Increase of oxidized/total coenzyme Q-10 ratio in cerebrospinal fluid in patients with Parkinson’s disease

Isobe, Chiaki; Murata, Tetsuya; Sato, Chigumi; Terayama, Yasuo

doi:10.1016/j.jocn.2005.12.023

Cited by 21 publications

(18 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4 ). The present in vivo findings demon- In comparing AD to other neurodegenerative diseases, we note that, for the AD group, oxidized CoQ-10 in the CSF (5.0 8 1.2 n M ) was also significantly greater in an untreated Parkinson's disease (PD) group (5.2 8 1.5 nM) [19] and an untreated amyotrophic lateral sclerosis (ALS) group (5.6 8 1.6 nM) [20] relative to the normal control group (1.9 8 1.3 nM). On the other hand, there were no significant differences in the reduced CoQ-10 in normal controls from each of these studies.…”

Section: Discussionmentioning

confidence: 64%

“…The most notable result is that the percentage of oxidized/total CoQ-10 in CSF (%CoQ10) shifted; the percentage of oxidized CoQ-10 was significantly higher in the untreated PD group (80.3 8 17.9%) [19] and the untreated ALS group (84.2 8 10.4%) [20] compared to the normal control group (41.3 8 10.4%). These findings support the hypothesis that oxidative stress, as a pathogenic pathway, contributes to AD, PD and ALS, which are representative of neurodegenerative diseases.…”

Section: Discussionmentioning

confidence: 99%

“…Concentrations of oxidized and reduced forms of CSF CoQ-10 were measured as previously described (table 1) [19] .…”

Section: Csf Analysismentioning

confidence: 99%

See 2 more Smart Citations

Increase in the Oxidized/Total Coenzyme Q-10 Ratio in the Cerebrospinal Fluid of Alzheimer’s Disease Patients

Isobe

Abe

Terayama

2009

Dement Geriatr Cogn Disord

Self Cite

View full text Add to dashboard Cite

Background/Aim: The contribution of mitochondrial dysfunction and oxidative stress to the pathogenesis of Alzheimer’s disease (AD) has previously been described. We aimed to investigate whether the balance between the oxidized and reduced forms of coenzyme Q-10 (CoQ-10) is related to the pathogenesis of AD. Materials and Method: Thirty patients with AD (69.0 ± 4.1 years) and 30 healthy control subjects (63.8 ± 16.4 years) were enrolled in this study. Concentrations of oxidized CoQ-10 and reduced CoQ-10 were measured by high-performance liquid chromatography using an electrochemical detector. Results: The percentage of oxidized/total CoQ-10 in the cerebrospinal fluid (%CoQ-10, CSF) was significantly higher in the untreated AD group (78.2 ± 18.8%) than in the control group (41.3 ± 10.4%, p < 0.001), and there was a significant negative correlation between %CoQ-10 and the duration of the illness (r_s = –0.93, p < 0.001). Conclusion: These findings in living AD patients suggest a possible role for %CoQ-10 in the pathogenesis of the early stage of AD development.

show abstract

Section: Discussionmentioning

confidence: 64%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Increase in the Oxidized/Total Coenzyme Q-10 Ratio in the Cerebrospinal Fluid of Alzheimer’s Disease Patients

Isobe

Abe

Terayama

2009

Dement Geriatr Cogn Disord

Self Cite

View full text Add to dashboard Cite

show abstract

“…The %CoQ 10 in the CSF of PD patients showed significant negative correlation with the duration of illness. These findings in living patients provide in vivo evidence for a possible role for %CoQ 10 in the pathogenesis in the early stages of PD development [172].…”

Section: Coenzyme Q10mentioning

confidence: 61%

“…The levels of CoQ 10 in PD analyzed in blood samples, failed to find consensus between the findings; some studies have reported decreased plasma levels, whereas others found no significant changes [170,171]. Recently, the concentrations of oxidized CoQ 10 and reduced CoQ 10 in the cerebrospinal fluid (CSF) of patients with PD has been examined in order to determine whether the balance in oxidized and reduced CoQ 10 is related to the pathogenesis of PD [172]. The percentage of oxidized/total CoQ 10 (%CoQ 10) in the CSF was significantly higher in the untreated PD group compared to the normal control group.…”

Section: Coenzyme Q10mentioning

confidence: 99%

Will it Ever Become Possible to Prevent Dopaminergic Neuronal Degeneration?

Giovanni

2008

CNSNDDT

View full text Add to dashboard Cite

Abstract:Parkinson's disease (PD) is the second leading age-related degenerative brain disease in the world affecting millions of people. This neurological disorder disrupts the quality of life of patients and their families, exerts an enormous emotional and physical strain on caregivers, and has a large cost for society. Moreover, the increasing numbers of elderly people in the population will result in a sharp increase in the prevalence of PD. The understanding of its pathophysiology and treatment has advanced at a very impressive rate during past decades. Nevertheless, PD is still fatal and there is at present no cure for it. Furthermore, there are no proven therapies for prevention of PD and although evidence exists of risk and protective factors, this is not strong enough to warrant specific measures in an attempt to diminish risk or enhance protection. Drug development programmes are engaged in finding neuroprotective and neurorestorative therapies or, even better, discovering drugs able to rejuvenate the dopaminergic neurons. The latest developments in this promising field will be discussed with reference to the current literature together with the advantages and pitfalls of suggested drugs. Finally, an analysis of the role of various dietary recommendations, lifestyle, environmental and other factors in reducing the risk of PD is carried out.

show abstract

Neurochemical biomarkers in the differential diagnosis of movement disorders

Mollenhauer

Trenkwalder

2009

Movement Disorders

View full text Add to dashboard Cite

In recent years, the neurochemical analysis of neuronal proteins in cerebrospinal fluid (CSF) has become increasingly accepted for the diagnosis of neurodegenerative dementia diseases such as Alzheimer's disease and Creutzfeldt-Jakob disease. CSF surrounds the central nervous system, and in the composition of CSF proteins one finds brain-specific proteins that are prioritized from blood-derived proteins. Levels of specific CSF proteins could be very promising biomarkers for central nervous system diseases. We need the development of more easily accessible biomarkers, in the blood. In neurodegenerative diseases with and without dementia, studies on CSF and blood proteins have investigated the usefulness of biomarkers in differential diagnosis. The clinical diagnoses of Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration still rely mainly on clinical symptoms as defined by international classification criteria. In this article, we review CSF biomarkers in these movement disorders and discuss recent published reports on the neurochemical intra vitam diagnosis of neurodegenerative disorders (including recent CSF alpha-synuclein findings).

show abstract

Increase of oxidized/total coenzyme Q-10 ratio in cerebrospinal fluid in patients with Parkinson’s disease

Cited by 21 publications

References 21 publications

Increase in the Oxidized/Total Coenzyme Q-10 Ratio in the Cerebrospinal Fluid of Alzheimer’s Disease Patients

Increase in the Oxidized/Total Coenzyme Q-10 Ratio in the Cerebrospinal Fluid of Alzheimer’s Disease Patients

Will it Ever Become Possible to Prevent Dopaminergic Neuronal Degeneration?

Neurochemical biomarkers in the differential diagnosis of movement disorders

Contact Info

Product

Resources

About